ASLANIAN ROBERT G has a total of 29 patent applications. Its first patent ever was published in 1998. It filed its patents most often in WIPO (World Intellectual Property Organization) and United States. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and environmental technology are ADVINUS THERAPEUTICS PRIVATE LTD, NEURO3D and CYTOPIA RES PTY LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 26 | |
#2 | United States | 3 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Heterocyclic compounds | |
#3 | Medical preparations | |
#4 | Steroids | |
#5 | Climate change mitigation in goods production |
# | Name | Total Patents |
---|---|---|
#1 | Aslanian Robert G | 29 |
#2 | Palani Anandan | 12 |
#3 | Mccormick Kevin D | 11 |
#4 | Berlin Michael Y | 11 |
#5 | Boyce Christopher W | 8 |
#6 | Xiao Dong | 8 |
#7 | Huang Xianhai | 8 |
#8 | Zheng Junying | 6 |
#9 | De Lera Ruiz Manuel | 6 |
#10 | Rao Ashwin U | 5 |
Publication | Filing date | Title |
---|---|---|
US2013210805A1 | Quinazolinone-type compounds as CRTH2 antagonists | |
WO2012047772A2 | Imidazole derivatives | |
WO2010045303A2 | Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof | |
WO2010009210A2 | Acetylsalicyclic acid derivatives useful to treat metabolic syndromes | |
WO2009105504A2 | Functionally selective alpha2c adrenoreceptor agonists |